Pyxis Oncology Q3 EPS Estimate Reduced by Leerink Partnrs

Pyxis Oncology, Inc. (NASDAQ:PYXS - Free Report) - Analysts at Leerink Partnrs reduced their Q3 2024 EPS estimates for Pyxis Oncology in a research note issued to investors on Tuesday, October 15th. Leerink Partnrs analyst J. La. Rosa now anticipates that the company will post earnings of ($0.35) per share for the quarter, down from their prior forecast of ($0.28). The consensus estimate for Pyxis Oncology's current full-year earnings is ($1.07) per share. Leerink Partnrs also issued estimates for Pyxis Oncology's Q4 2024 earnings at ($0.37) EPS, FY2024 earnings at ($1.07) EPS, FY2025 earnings at ($1.33) EPS, FY2026 earnings at ($1.16) EPS, FY2027 earnings at ($1.17) EPS and FY2028 earnings at ($1.07) EPS.

Pyxis Oncology (NASDAQ:PYXS - Get Free Report) last posted its earnings results on Wednesday, August 14th. The company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.04.

A number of other equities research analysts also recently commented on the stock. HC Wainwright reissued a "buy" rating and issued a $7.00 price objective on shares of Pyxis Oncology in a research report on Friday, August 16th. Stifel Nicolaus initiated coverage on shares of Pyxis Oncology in a research note on Thursday, August 8th. They set a "buy" rating and a $10.00 price target for the company. Finally, Royal Bank of Canada restated an "outperform" rating and issued a $7.00 target price on shares of Pyxis Oncology in a research note on Thursday, September 19th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $9.00.

Pyxis Oncology Price Performance

Shares of PYXS stock traded up $0.52 during trading hours on Friday, hitting $3.75. The company had a trading volume of 1,669,033 shares, compared to its average volume of 626,795. The company's fifty day moving average is $3.53 and its 200 day moving average is $3.79. Pyxis Oncology has a fifty-two week low of $1.35 and a fifty-two week high of $6.85. The stock has a market capitalization of $222.83 million, a PE ratio of -3.02 and a beta of 1.27.

Institutional Trading of Pyxis Oncology

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Fullcircle Wealth LLC bought a new stake in shares of Pyxis Oncology in the second quarter worth $40,000. SG Americas Securities LLC bought a new position in shares of Pyxis Oncology during the third quarter worth about $58,000. The Manufacturers Life Insurance Company bought a new position in shares of Pyxis Oncology during the second quarter worth about $65,000. Cetera Advisors LLC acquired a new stake in Pyxis Oncology in the first quarter worth about $100,000. Finally, Schulhoff & Co. Inc. lifted its holdings in Pyxis Oncology by 90.9% in the second quarter. Schulhoff & Co. Inc. now owns 42,000 shares of the company's stock worth $139,000 after purchasing an additional 20,000 shares during the period. Institutional investors own 39.09% of the company's stock.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.